BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 21152689)

  • 41. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
    Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S
    World J Surg Oncol; 2007 Jun; 5():68. PubMed ID: 17584499
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Positron Emission Tomography (PET) and breast cancer in clinical practice.
    Lavayssière R; Cabée AE; Filmont JE
    Eur J Radiol; 2009 Jan; 69(1):50-8. PubMed ID: 18814983
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
    Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
    Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
    Giammarile F; Billotey C; Lombard-Bohas C; Le Bars D; Bournaud C; Masson S; Walter T; Houzard C; Scoazec JY; Hervieu V; Vuillez JP; Cornu C; Janier M; Borson-Chazot F
    Nucl Med Commun; 2011 Feb; 32(2):91-7. PubMed ID: 21076344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PET beyond ¹⁸F-FDG: second generation PET tracers in clinical oncology.
    Brouwers AH; Glaudemans AW; De Vries EF
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):1-3. PubMed ID: 25854554
    [No Abstract]   [Full Text] [Related]  

  • 48. Nuclear medicine studies of the prostate, testes, and bladder.
    Jana S; Blaufox MD
    Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How to use PET/CT in the evaluation of response to radiotherapy.
    Decazes P; Thureau S; Dubray B; Vera P
    Q J Nucl Med Mol Imaging; 2018 Jun; 62(2):152-164. PubMed ID: 29186937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.
    Basu S; Alavi A
    PET Clin; 2016 Jul; 11(3):203-7. PubMed ID: 27321025
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Standardization and quantification in PET/CT imaging: tracers beyond FDG.
    Antunovic L; Rodari M; Rossi P; Chiti A
    PET Clin; 2014 Jul; 9(3):259-66. PubMed ID: 25030389
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The use of 18F-fluorothymidine and 18F-fluorocholine in imaging with positron emission tomography].
    Skoura E; Datseris IE
    Hell J Nucl Med; 2010; 13(1):88-90. PubMed ID: 20411184
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer.
    Monazzam A; Josephsson R; Blomqvist C; Carlsson J; Långström B; Bergström M
    Breast Cancer Res; 2007; 9(4):R45. PubMed ID: 17659092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 11C/ 18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended?
    Nanni C; Castellucci P; Farsad M; Rubello D; Fanti S
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1704-5. PubMed ID: 17619877
    [No Abstract]   [Full Text] [Related]  

  • 55. Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model.
    Emonds KM; Swinnen JV; Lerut E; Koole M; Mortelmans L; Mottaghy FM
    EJNMMI Res; 2013 Apr; 3(1):31. PubMed ID: 23618081
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proliferation markers for the differential diagnosis of tumor and inflammation.
    van Waarde A; Elsinga PH
    Curr Pharm Des; 2008; 14(31):3326-339. PubMed ID: 19075707
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PET imaging of proliferation with pyrimidines.
    Tehrani OS; Shields AF
    J Nucl Med; 2013 Jun; 54(6):903-12. PubMed ID: 23674576
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New PET imaging agents in the management of solid cancers.
    Garcia C; Gebhart G; Flamen P
    Curr Opin Oncol; 2012 Nov; 24(6):748-55. PubMed ID: 22913970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography.
    Wijsman R; Kaanders JH; Oyen WJ; Bussink J
    Q J Nucl Med Mol Imaging; 2013 Sep; 57(3):244-56. PubMed ID: 24045621
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PET/CT imaging in different types of lung cancer: an overview.
    Ambrosini V; Nicolini S; Caroli P; Nanni C; Massaro A; Marzola MC; Rubello D; Fanti S
    Eur J Radiol; 2012 May; 81(5):988-1001. PubMed ID: 21458181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.